178 related articles for article (PubMed ID: 18473810)
1. SRC family kinases as potential therapeutic targets for malignancies and immunological disorders.
Benati D; Baldari CT
Curr Med Chem; 2008; 15(12):1154-65. PubMed ID: 18473810
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
3. Synthetic SRC-kinase domain inhibitors and their structural requirements.
Schenone S; Manetti F; Botta M
Anticancer Agents Med Chem; 2007 Nov; 7(6):660-80. PubMed ID: 18045061
[TBL] [Abstract][Full Text] [Related]
4. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy.
Johnson FM; Gallick GE
Anticancer Agents Med Chem; 2007 Nov; 7(6):651-9. PubMed ID: 18045060
[TBL] [Abstract][Full Text] [Related]
5. Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits.
Ping P; Zhang J; Zheng YT; Li RC; Dawn B; Tang XL; Takano H; Balafanova Z; Bolli R
Circ Res; 1999 Sep; 85(6):542-50. PubMed ID: 10488057
[TBL] [Abstract][Full Text] [Related]
6. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
Krystal GW; DeBerry CS; Linnekin D; Litz J
Cancer Res; 1998 Oct; 58(20):4660-6. PubMed ID: 9788619
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
8. Src continues aging: current and future clinical directions.
Kopetz S; Shah AN; Gallick GE
Clin Cancer Res; 2007 Dec; 13(24):7232-6. PubMed ID: 18094400
[TBL] [Abstract][Full Text] [Related]
9. Src signaling in cancer invasion.
Guarino M
J Cell Physiol; 2010 Apr; 223(1):14-26. PubMed ID: 20049846
[TBL] [Abstract][Full Text] [Related]
10. SRC inhibitors as potential therapeutic agents for human cancers.
Trevino JG; Summy JM; Gallick GE
Mini Rev Med Chem; 2006 Jun; 6(6):681-7. PubMed ID: 16787379
[TBL] [Abstract][Full Text] [Related]
11. The development of novel and selective p56lck tyrosine kinase inhibitors.
Bullington JL; Cameron JC; Davis JE; Dodd JH; Harris CA; Henry JR; Pellegrino-Gensey JL; Rupert KC; Siekierka JJ
Bioorg Med Chem Lett; 1998 Sep; 8(18):2489-94. PubMed ID: 9873567
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Ly49D/DAP12 signal transduction by Src-family kinases and CD45.
Mason LH; Willette-Brown J; Taylor LS; McVicar DW
J Immunol; 2006 Jun; 176(11):6615-23. PubMed ID: 16709819
[TBL] [Abstract][Full Text] [Related]
13. Antagonists of the Src homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70.
García-Echeverria C
Curr Med Chem; 2001 Nov; 8(13):1589-604. PubMed ID: 11562287
[TBL] [Abstract][Full Text] [Related]
14. Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56(Lck).
Chen P; Norris D; Iwanowicz EJ; Spergel SH; Lin J; Gu HH; Shen Z; Wityak J; Lin TA; Pang S; De Fex HF; Pitt S; Shen DR; Doweyko AM; Bassolino DA; Roberge JY; Poss MA; Chen BC; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2002 May; 12(10):1361-4. PubMed ID: 11992777
[TBL] [Abstract][Full Text] [Related]
15. Src and focal adhesion kinase as therapeutic targets in cancer.
Brunton VG; Frame MC
Curr Opin Pharmacol; 2008 Aug; 8(4):427-32. PubMed ID: 18625340
[TBL] [Abstract][Full Text] [Related]
16. Implications for Src kinases in hematopoiesis: signal transduction therapeutics.
Sinha S; Corey SJ
J Hematother Stem Cell Res; 1999 Oct; 8(5):465-80. PubMed ID: 10791898
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
Chen P; Norris D; Das J; Spergel SH; Wityak J; Leith L; Zhao R; Chen BC; Pitt S; Pang S; Shen DR; Zhang R; De Fex HF; Doweyko AM; McIntyre KW; Shuster DJ; Behnia K; Schieven GL; Barrish JC
Bioorg Med Chem Lett; 2004 Dec; 14(24):6061-6. PubMed ID: 15546730
[TBL] [Abstract][Full Text] [Related]
18. Src tyrosine kinases mediate crystalline silica-induced NF-kappaB activation through tyrosine phosphorylation of IkappaB-alpha and p65 NF-kappaB in RAW 264.7 macrophages.
Kang JL; Jung HJ; Lee K; Kim HR
Toxicol Sci; 2006 Apr; 90(2):470-7. PubMed ID: 16431847
[TBL] [Abstract][Full Text] [Related]
19. The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy.
Lieu C; Kopetz S
Clin Colorectal Cancer; 2010 Apr; 9(2):89-94. PubMed ID: 20378502
[TBL] [Abstract][Full Text] [Related]
20. Discovery of thienopyridines as Src-family selective Lck inhibitors.
Abbott L; Betschmann P; Burchat A; Calderwood DJ; Davis H; Hrnciar P; Hirst GC; Li B; Morytko M; Mullen K; Yang B
Bioorg Med Chem Lett; 2007 Mar; 17(5):1167-71. PubMed ID: 17234410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
